Review decision - August 2009

Review of NICE Technology Appraisal Guidance No 101; Docetaxel for the treatment of hormone refractory prostate cancer

Review decision

The Institute was proposing that a review of the guidance should be deferred to June 2013.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.¬†After consideration of all of the comments (included in appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal. We will therefore schedule a review to again assess the evidence in April 2013.

This page was last updated: 30 March 2010